Ambrx Biopharma Inc.
Index- P/E- EPS (ttm)-1.75 Insider Own- Shs Outstand42.22M Perf Week4.92%
Market Cap106.12M Forward P/E- EPS next Y-0.37 Insider Trans- Shs Float5.51M Perf Month-30.75%
Income-68.10M PEG- EPS next Q- Inst Own51.10% Short Float0.18% Perf Quarter-34.05%
Sales7.50M P/S14.15 EPS this Y-301.70% Inst Trans1.41% Short Ratio1.09 Perf Half Y-69.22%
Book/sh4.50 P/B0.62 EPS next Y11.90% ROA- Target Price9.33 Perf Year-86.00%
Cash/sh4.44 P/C0.62 EPS next 5Y21.70% ROE- 52W Range2.52 - 22.87 Perf YTD-69.32%
Dividend- P/FCF- EPS past 5Y- ROI-33.90% 52W High-87.89% Beta-
Dividend %- Quick Ratio7.20 Sales past 5Y- Gross Margin- 52W Low9.92% ATR0.30
Employees81 Current Ratio7.20 Sales Q/Q-67.70% Oper. Margin- RSI (14)33.26 Volatility9.01% 10.39%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.00 Prev Close2.77
ShortableYes LT Debt/Eq0.00 EarningsMay 02 AMC Payout- Avg Volume9.15K Price2.77
Recom1.70 SMA20-15.13% SMA50-24.56% SMA200-60.44% Volume0 Change0.00%
Apr-07-22Initiated Robert W. Baird Outperform $16
Feb-28-22Initiated Goldman Neutral $6
Jul-13-21Initiated Goldman Buy $53
Jul-13-21Initiated Cowen Outperform
Jul-13-21Initiated BofA Securities Buy $26
Jul-05-22 04:05PM  
Jun-28-22 04:05PM  
Jun-20-22 08:20AM  
Jun-06-22 08:00AM  
May-27-22 04:05PM  
May-17-22 04:05PM  
May-06-22 04:05PM  
May-02-22 04:05PM  
Apr-26-22 11:01PM  
Apr-25-22 04:05PM  
Apr-21-22 04:05PM  
Apr-14-22 09:55AM  
Mar-08-22 08:00AM  
Feb-28-22 04:05PM  
Feb-15-22 08:00AM  
Feb-07-22 08:00AM  
Dec-29-21 05:37AM  
Dec-09-21 12:30PM  
Nov-19-21 04:05PM  
Nov-08-21 04:15AM  
Nov-04-21 08:00AM  
Nov-01-21 04:05PM  
Oct-28-21 04:05PM  
Oct-04-21 08:00AM  
Sep-09-21 04:30PM  
Aug-03-21 08:00AM  
Jul-18-21 11:39AM  
Jun-30-21 08:00AM  
Jun-17-21 11:15PM  
Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers. In addition, it is developing other multiple product candidates targeting immuno-oncology applications, which include ARX822, a fab-small molecule bispecific that is in preclinical development for cancers; and ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the ß and gamma receptors on the cytotoxic T cell. Ambrx Biopharma Inc. has collaborations with Bristol Myers Squibb Company; AbbVie Inc.; BeiGene; Sino Biopharmaceutical Co., Ltd.; NovoCodex; and Elanco Animal Health. The company was incorporated in 2003 and is headquartered in La Jolla, California.